Richard Perrin Lab

Novel cerebrospinal fluid biomarkers for early diagnosis, prognosis, and staging of neurodegenerative diseases. Read More

Research Overview

Richard Perrin’s laboratory studies the cerebrospinal fluid proteome to identify new biomarkers for early diagnosis, prognosis, staging and monitoring of neurodegenerative diseases.  Such biomarkers will be essential for maximizing the efficiency, shortening the duration and reducing the cost of clinical trials, and should therefore accelerate the evaluation and discovery of effective treatments.  Additionally, they may provide novel insights into neurodegenerative pathophysiology and suggest unanticipated candidate targets for therapy.